Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal

Cancer Science

Volumn 94, Issue 1, 2003, Pages 15-21

  Tsuruo, Takashi ^a,b   Naito, Mikihiko ^a   Tomida, Akihiro ^a   Fujita, Naoya ^a   Mashima, Tetsuo ^b   Sakamoto, Hiroshi ^a,b   Haga, Naomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ABC TRANSPORTER; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CAMPTOTHECIN; CISPLATIN; CYCLOSPORIN A; CYTARABINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; GEFITINIB; GELDANAMYCIN; GLUCOSE; GLYCOPROTEIN P; IMATINIB; LACTOYLGLUTATHIONE LYASE; MITOMYCIN C; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PROTEIN KINASE B; TRASTUZUMAB; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE;

APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CELL SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DETOXIFICATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; ENZYME DEGRADATION; GENETIC CODE; GLYCOLYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOXIA; MOLECULAR SIZE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRESS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL HYPOXIA; CELL NUCLEUS; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTOYLGLUTATHIONE LYASE; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; NEOPLASMS; OXIDATIVE STRESS; P-GLYCOPROTEIN; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 0037648896     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01345.x     Document Type: Review

References (50)

1. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988; 79: 285 -96.
2. Sugimoto Y, Tsuruo T. DNA-mediated transfer and cloning of a human multidrug-resistant gene of Adriamycin-resistant myelogenous leukemia K562. Cancer Res 1987; 47: 2620-5.
3. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785-9.
4. Hamada H, Tsuruo T. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem 1988: 263: 1454-8.
5. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem 1988; 263: 11887-91.
6. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72.
7. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42: 4730-3.
8. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983; 43: 2267-72.
9. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983; 43: 2905-10.
10. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, Tsuruo T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995; 35: 271-7.
11. Natio M, Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 1989; 49: 1452-5.
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
13. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383-91.
14. Hamada H, Miura K, Ariyoshi K, Heike Y, Sato S, Kameyama K, Kurosawa Y, Tsuruo T. Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein. Cancer Res 1990; 50: 3167-71.
15. Watanabe T, Naito M, Kokubo N, Tsuruo T. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 1997; 89: 512-8.
16. Sugimoto Y, Sato S, Tsukahara S, Suzuki M, Okochi E, Gottesman MM, Pastan I, Tsuruo T. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Ther 1997; 4: 51-8.
17. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
18. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999; 14: 169-77.
19. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, Arnold SM. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 2002; 3: 411-21.
20. Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 1987; 84: 3278-82.
21. Yun J, Tomida A, Nagata K, Tsuruo T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 1995; 7: 583-90.
22. Rubin EH, Li TK, Duann P, Liu LF. Cellular resistance to topoisomerase poisons. Cancer Treat Res 1996; 87: 243-60.
23. Kim HD, Tomida A, Ogiso Y, Tsuruo T. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 1999; 180: 97-104.
24. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000; 60: 2429-34.
25. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8: S49-54.
26. Ogiso Y, Tomida A, Kim HD, Tsuruo T. Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem Biophys Res Commun 1999; 258: 449-52.
27. Ogiso Y, Tomida A, Tsuruo T. Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res 2002; 62: 5008-12.
28. Horie K, Tomida A, Sugimoto Y, Yasugi T, Yoshikawa H, Taketani Y, Tsuruo T. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Oncogene 2002; 21: 7913-22.
29. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-9.
30. Kataoka S, Naito M, Tomida A, Tsuruo T. Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp Cell Res 1994; 215: 199-205.
31. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95: 3214-8.
32. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 2001; 7: 2513-8.
33. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990; 269: 1-11.
34. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N-alpha-acetylcysteine, and N-alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994: 269: 32299-305.
35. Thornalley PK. Esterification of reduced glutathione. Biochem J 1991; 275: 535-9.
36. Godbout JP, Pesavento J, Hartman ME, Manson SR, Freund GG. Methylglyoxal enhances cisplatin-induced cytotoxicity by activating protein kinase Cδ. J Biol Chem 2002; 277: 2554-61.
37. Van Herreweghe F, Mao J, Chaplen FW, Grooten J, Gevaert K, Vandekerckhove J, Vancompernolle K. Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc Natl Acad Sci USA 2002; 99: 949-54.
38. Sakamoto H, Mashima T, Yamamoto K, Tsuruo, T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal-modification. J Biol Chem 2002; 277: 45770-5.
39. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346: 561-76.
40. Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002; 277: 28706-13.
41. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-7.
42. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, Tsuruo T, Sessa WC. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002; 90: 866-73.
43. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2002; 277: 10346-53.
44. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002; 21: 1159-66.
45. Bachelder RE, Wendt MA, Fujita N, Tsuruo T, Mercurio AM. The cleavage of Akt/PKB by death receptor signaling is an important event in detachment-induced apoptosis. J Biol Chem 2001; 276: 34702-7.
46. Rokudai S, Fujita N, Hashimoto Y, Tsuruo T. Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. J Cell Physiol 2000; 182: 290-6.
47. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21: 1727-38.
48. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival-signaling pathway during topotecan-induced apoptosis. Cancer Res 2000; 60: 5303-9.
49. Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of PI3K-Akt signaling pathway. Int J Cancer 2002; 98: 36-41.
50. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, Toda S, Hirohashi S. Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogenous intrahepatic metastasis of liver cancer. Cancer Res 2002; 62: 2971-5.